2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 704

Improving Patient-Centered Care by Utilizing Lupus Wellness Program
Abstract Number: 705

A Tale of Three Cohorts: SLE Criteria in Developed vs Developing Countries
Abstract Number: 706

Neuronal BC RNAs: Systemic Lupus Erythematosus Autoantibodies Cause Dendritic Transport Impairments
Abstract Number: 707

Severity and Evolution over Time of Gastro-Intestinal Involvement in Patients with Systemic Sclerosis in Two Large and Independent Cohorts
Abstract Number: 708

Improvement and Stabilization of Lung Function in Patients with SSc-ILD Treated with Nintedanib vs Placebo in a Randomized, Placebo-Controlled Phase III Trial: Proportions of Patients with FVC Changes Using Cutoffs Previously Proposed to Define Minimally Clinically Important Differences
Abstract Number: 709

Structural Abnormalities of the Optic Nerve Head and Retinal Nerve Fiber Layer Using Optical Coherence Tomography in Patients with Systemic Sclerosis
Abstract Number: 710

Relationship Between High-Resolution Computer Tomography and FVC% Predicted for Classification of Pulmonary Hypertension in Systemic Sclerosis
Abstract Number: 711

Ultrasound Evaluation of the Hands in Patients with Systemic Sclerosis: Osteophytosis Is a Major Contributor to Tender Joints
Abstract Number: 712

Safety and Tolerability of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis Based on Demographic Characteristics
Abstract Number: 713

NEMO Score in Nailfold Videocapillaroscopy Is a Good Tool to Assess Both Steady State Levels and Overtime Changes of Disease Activity in Patients with Systemic Sclerosis: A Comparison with Both the Composite EScSG and EUSTAR Indices for This Disease Status Entity
Abstract Number: 714

Characteristics of Patients with Systemic Sclerosis in the Rheumatology Informatics System for Effectiveness (RISE) Registry
Abstract Number: 715

Imaging Technique (R)evolution to Measure the Digital Microcirculatory Flow in Systemic Sclerosis: A Systematic Review
Abstract Number: 716

Looking for a “Very Early” Nailfold Capillaroscopic Pattern: Specific Alterations of Nailfold Capillaries May Precede the Validated Scleroderma-Patterns in Systemic Sclerosis Patients
Abstract Number: 717

Dental Health in Systemic Sclerosis Patients Risk Factors and Comorbidities
Abstract Number: 718

Diagnosing Pulmonary Hypertension Using the Proposed 6th World Symposium on Pulmonary Hypertensions New Definitions

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.